ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 62 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $156,749,622 | -19.2% | 7,814,039 | +13.6% | 2.82% | -14.1% |
Q2 2023 | $194,022,823 | +249.6% | 6,877,803 | +113.1% | 3.28% | +222.1% |
Q1 2023 | $55,504,400 | +27.8% | 3,227,000 | +49.6% | 1.02% | +18.9% |
Q4 2022 | $43,432,212 | +7.7% | 2,156,515 | +15.9% | 0.86% | +7.9% |
Q3 2022 | $40,309,000 | +42.9% | 1,861,000 | +85.4% | 0.79% | +31.5% |
Q2 2022 | $28,212,000 | -19.7% | 1,004,000 | +31.9% | 0.60% | +9.6% |
Q1 2022 | $35,113,000 | -21.0% | 761,000 | +43.9% | 0.55% | -3.2% |
Q4 2021 | $44,468,000 | +26.1% | 529,000 | 0.0% | 0.57% | +22.2% |
Q3 2021 | $35,253,000 | +57.6% | 529,000 | +25.8% | 0.46% | +55.0% |
Q2 2021 | $22,365,000 | -38.0% | 420,400 | -49.5% | 0.30% | -43.9% |
Q1 2021 | $36,100,000 | -16.5% | 832,000 | 0.0% | 0.54% | -19.3% |
Q4 2020 | $43,214,000 | +49.9% | 832,000 | -8.7% | 0.66% | +17.6% |
Q3 2020 | $28,822,000 | -32.2% | 911,416 | -0.4% | 0.56% | -39.0% |
Q2 2020 | $42,496,000 | – | 914,705 | – | 0.92% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |